Ann: Dr Adrian Attard Trevisan, page-11

Agreed.

This has been a big disappointment:

1. The Carrick Institute study's final results fell incredibly short of the expectations built by the interim announcement that some children were measuring "within the normal range".
2. The distribution agreements that the company worked so hard to put in place, the redesign initiative, the manufacturing agreement... all have come to nothing, resulting in the necessity of a radical change in strategy.
3. Now a terrible blow to the credibility of a key person involved in developing the product, with an unavoidable on the credibility of the product.

I feel terribly for those holders and watchers who had such high hopes for an effective, accessible treatment for kids with the condition. Regardless of whether the product is effective, this development will mean even more difficulty, expense and delays in bringing the product to market.

I am sorry.